*Purpose: At present,donor derived parvovirus B19 infections are rarely reported. Thus, the incidence of donor derived parvovirus B19 infections in solid organ transplant recipients is still unknown for lacking of surveillance studies. Similarly, whether the donor need to do routine screening of parvovirus B19 and whether organs from the parvovirus B19 infected donor could be accepted also remains unknown.

*Methods: This retrospective study aims to evaluate the donor derived parvovirus B19 infections in 320 living and 476 deceased donors kidney transplantation from January 2016 to December 2017. Serum parvovirus B19 DNA of living donors and their corresponding recipients were measured before and after the transplantation, while the measurement of recipients with deceased donors was only done in those after the transplantation. Furthermore, if parvovirus B19 infection occurred, serum of recipients and their corresponding donors before transplantation would be tested.

*Results: 7 (2.2%) living donors were B19 viremia positive before the donation, of which an asymptomatic viremia occurred in one recipient and the B19 viremia turned negative at early stage after transplantation. Donor derived parvovirus B19 infections occurred in 6 (1.3%) deceased donor kidney transplantation at the 7^th day after operation, which were successfully controlled. The new parvovirus B19 infections after two weeks of operation were irrelevant to the donors.

*Conclusions: The incidence of donor derived parvovirus B19 infection was 0.3%, 1.3% in living and deceased transplantation, respectively. Parvovirus B19 needed to be screened for deceased donors, which was not the same for living donors. Moreover, kidneys of the donors with parvovirus B19 infection were acceptable.

« Back to 2020 American Transplant Congress